scispace - formally typeset
C

Charles M. Cleland

Researcher at New York University

Publications -  232
Citations -  6688

Charles M. Cleland is an academic researcher from New York University. The author has contributed to research in topics: Population & Medicine. The author has an hindex of 42, co-authored 208 publications receiving 5696 citations. Previous affiliations of Charles M. Cleland include National Development and Research Institutes & University of Maryland, College Park.

Papers
More filters
Journal ArticleDOI

Prevalence and Characteristics of Chronic Pain Among Chemically Dependent Patients in Methadone Maintenance and Residential Treatment Facilities

TL;DR: Chronic severe pain is prevalent among patients in substance abuse treatment, especially MMTP patients, and self-medication for pain with psychoactive drugs appears especially problematic among substance users who enroll in drug-free treatment programs.
Journal ArticleDOI

The Effects of Behavioral/Cognitive-Behavioral Programs on Recidivism

TL;DR: The CDATE project coded studies of treatment/intervention programs in prison, jail, probation, or parole settings reported from 1968 through 1996 as mentioned in this paper, and meta-analyses were conducted on the 69 primary research studies on the effectiveness of behavioral and cognitive-behavioral treatment in reducing recidivism for offenders.
Journal ArticleDOI

Prescription opioid abuse among enrollees into methadone maintenance treatment.

TL;DR: A multi-state survey of opioid dependent persons enrolling in 72 methadone maintenance treatment programs was conducted to determine the prevalence of prescription opioid (PO) abuse, factors associated with PO abuse and sources for POs.
Journal ArticleDOI

Incidence of sexually transmitted hepatitis C virus infection in HIV-positive men who have sex with men.

TL;DR: The high reinfection rates and the attributable risk analysis suggest the existence of a subset of HIV-positive MSM with recurring sexual exposure to HCV, which is likely to become chronic and liver fibrosis progression is accelerated in this population.